Results 121 to 130 of about 56,351 (295)

The synthetic cannabinoids menace: a review of health risks and toxicity

European Journal of Medical Research
Synthetic cannabinoids (SCs) are chemically classified as psychoactive substances that target the endocannabinoid system in many body organs. SCs can initiate pathophysiological changes in many tissues which can be severe enough to damage the normal ...
Ayman Alzu’bi, Fatimah Almahasneh, Ramada Khasawneh, Ejlal Abu-El-Rub, Worood Bani Baker, Raed M. Al-Zoubi   +5 more
doaj   +1 more source

Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. [PDF]

, 2018
Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and dose-limiting side effect of cancer treatment that affects millions of cancer survivors throughout the world and current treatment options are extremely limited by their side effects ...
Mackie, Ken, Marty, Vincent N, Mulpuri, Yatendra, Munier, Joseph J, Schmidt, Brian L, Seltzman, Herbert H, Spigelman, Igor   +6 more
core   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Temporal and geographical patterns of nitazene detections in drug samples and biospecimens in the United States, 2019–2024

Addiction, EarlyView.
Abstract Background and aims Nitazenes are a novel subclass of synthetic opioids that have been increasingly implicated in the United States (US) overdose crisis. Despite their growing presence in the illicit drug supply, national trends have not been systematically evaluated.
David T. Zhu, Nicole D. Fitzgerald, Joseph J. Palamar, Alex J. Krotulski   +3 more
wiley   +1 more source

Determining the impact of cannabis use on tobacco cessation: Results from a prospective non‐randomized tobacco treatment trial

Addiction, EarlyView.
Abstract Background and aims Tobacco‐cannabis co‐use is associated with increased psychosocial and health harms; however, the treatment literature assessing the impact of co‐use has been mixed and suffers from critical limitations. To date, no prospective studies have evaluated the degree to which cannabis co‐use affects tobacco cessation, nor are ...
Erin A. McClure, Nathaniel Baker, Rachel L. Tomko, Kyle J. Walters, Elizabeth Chapman, Matthew J. Carpenter, Kevin M. Gray   +6 more
wiley   +1 more source

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, EarlyView.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

British Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr, Christiane Dings, Omar Zaher, Frederike Nordmeier, Nadja Walle, Matthias W. Laschke, Michael D. Menger, Peter H. Schmidt, Markus R. Meyer, Thorsten Lehr, Nadine Schaefer   +10 more
wiley   +1 more source

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data

Brazilian Journal of Psychiatry
Objective: Schizophrenia is a multifactorial disorder. It is known that a combination of extensive multiple common alleles may be involved in its etiology, each contributing with a small to moderate effect, and, possibly, some rare alleles with a much ...
Eduardo S. Gouvêa, Airton F. Santos Filho, Vanessa K. Ota, Vinicius Mrad, Ary Gadelha, Rodrigo A. Bressan, Quirino Cordeiro, Sintia I. Belangero   +7 more
doaj   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Update on the Role of Cannabinoid Receptors after Ischemic Stroke

Mediators of Inflammation, 2012
Cannabinoids are considered as key mediators in the pathophysiology of inflammatory diseases, including atherosclerosis. In particular, they have been shown to reduce the ischemic injury after acute cardiovascular events, such as acute myocardial ...
Luciano S. A. Capettini, Silvia Q. Savergnini, Rafaela F. da Silva, Nikos Stergiopulos, Robson A. S. Santos, François Mach, Fabrizio Montecucco   +6 more
doaj   +1 more source